> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AbbVie sNDA for Rinvoq in Axial Spondyloarthritis
- URL: https://www.fdaweb.com/abbvie-snda-for-rinvoq-in-axial-spondyloarthritis/
- Published: 2022-01-07T12:00:00.000Z
- Updated: 2026-09-14T17:27:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150890

AbbVie has submitted a supplemental NDA for Rinvoq (upadacitinib,15 mg once daily) for treating adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs. The submission is based on data from the Phase 3 SELECT-AXIS 2 clinical trial, which the company says demonstrated the treatment resulted in reductions in signs and symptoms of nr-axSpA, including back pain and inflammation, as well as improvements in physical function and disease activity at week 14 versus placebo. Axial spondyloarthritis is a chronic inflammatory spinal disease that causes patients to suffer from debilitating pain and decreased quality of life. Rinvoq is FDA-approved for treating rheumatoid and psoriatic arthritis.